| __timestamp | Intra-Cellular Therapies, Inc. | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 21226345 | 1271353000 |
| Thursday, January 1, 2015 | 87718074 | 1620577000 |
| Friday, January 1, 2016 | 93831530 | 2052295000 |
| Sunday, January 1, 2017 | 79419009 | 2075142000 |
| Monday, January 1, 2018 | 132166913 | 2186100000 |
| Tuesday, January 1, 2019 | 89124838 | 3036600000 |
| Wednesday, January 1, 2020 | 65782137 | 2735000000 |
| Friday, January 1, 2021 | 88845513 | 2908100000 |
| Saturday, January 1, 2022 | 134715000 | 3592500000 |
| Sunday, January 1, 2023 | 180142000 | 4439000000 |
| Monday, January 1, 2024 | 5132000000 |
Unlocking the unknown
In the competitive world of biopharmaceuticals, research and development (R&D) is the lifeblood of innovation. Over the past decade, Regeneron Pharmaceuticals, Inc. and Intra-Cellular Therapies, Inc. have demonstrated contrasting yet fascinating R&D investment strategies. Regeneron, a giant in the industry, has consistently allocated substantial resources, with a peak in 2023 where R&D expenses soared to nearly 4.4 billion dollars, marking a 250% increase since 2014. In contrast, Intra-Cellular Therapies, a smaller player, has shown a more modest but steady growth in R&D spending, culminating in a 2023 investment of approximately 180 million dollars, an impressive 750% rise from 2014. This divergence highlights the varied approaches companies take to fuel innovation and maintain competitive edges in the ever-evolving pharmaceutical landscape.
R&D Insights: How Merck & Co., Inc. and Regeneron Pharmaceuticals, Inc. Allocate Funds
Research and Development Expenses Breakdown: Pfizer Inc. vs Intra-Cellular Therapies, Inc.
Research and Development Expenses Breakdown: Regeneron Pharmaceuticals, Inc. vs Alnylam Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: Regeneron Pharmaceuticals, Inc. vs Summit Therapeutics Inc.
Regeneron Pharmaceuticals, Inc. or TG Therapeutics, Inc.: Who Invests More in Innovation?
Comparing Innovation Spending: Regeneron Pharmaceuticals, Inc. and ImmunityBio, Inc.
Regeneron Pharmaceuticals, Inc. or Arrowhead Pharmaceuticals, Inc.: Who Invests More in Innovation?
R&D Insights: How Regeneron Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc. Allocate Funds
R&D Insights: How Alnylam Pharmaceuticals, Inc. and Intra-Cellular Therapies, Inc. Allocate Funds
Research and Development Expenses Breakdown: Intra-Cellular Therapies, Inc. vs TG Therapeutics, Inc.
Research and Development Investment: Intra-Cellular Therapies, Inc. vs Ultragenyx Pharmaceutical Inc.
Intra-Cellular Therapies, Inc. or PTC Therapeutics, Inc.: Who Invests More in Innovation?